Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center
Transplant International · 20.08.2024 · 37
DOI: 10.3389/ti.2024.13220 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, online erschienen am 20.08.2024. Verfasst von Giulia Vanessa Re Sartò und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Milano, Italy. Hauptthemen laut MEDLINE: Kidney Transplantation, Immunosuppressive Agents, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We describe the epidemiology of cancer after kidney transplantation (KTx), investigating its risk factors and impact on therapeutic management and survival in KTx recipients (KTRs). The association between modification of immunosuppressive (IS) therapy after cancer and survival outcomes was analyzed. We collected data from 930 KTRs followed for 7 [1–19] years. The majority of KTRs received KTx from a deceased donor (84%). In total, 74% of patients received induction therapy with basiliximab and 26% with ATG. Maintenance therapy included steroids, calcineurin inhibitors, and mycophenolate. Patients with at least one cancer (CA+) amounted to 19%. NMSC was the most common tumor (55%). CA+ were older and had a higher BMI. Vasculitis and ADPKD were more prevalent in CA+. ATG was independently associated with CA+ and was related to earlier cancer development in survival and competing risk analyses ( p = 0.01 and <0.0001; basiliximab 89 ± 4 vs . ATG 40 ± 4 months). After cancer diagnosis, a significant prognostic impact was derived from the shift to mTOR inhibitors compared to a definitive IS drug suspension ( p = 0.004). Our data confirm the relevance of cancer as a complication in KTRs with ATG as an independent risk factor. An individualized choice of IS to be proposed at the time of KTx is crucial in the prevention of neoplastic risk. Finally, switching to mTORi could represent an important strategy to improve patient survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Milano, Italy.
- Department of Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca' Granda Ospedale Policlinico, Milan, Italy.
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
- Post-Graduate School of Specialization in Nephrology, University of Milan, Milan, Italy.
- Department of Biomedical and Clinical Sciences, Università di Milano, Milano, Italy.
Zitieren
APA
Re Sartò, G. V., Alfieri, C., Cosmai, L., Brigati, E., Campise, M., Regalia, A., Verdesca, S., Molinari, P., Pisacreta, A. M., Pirovano, M., Nardelli, L., Gallieni, M., & Castellano, G. (2024). Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center. Transplant International, 37. https://doi.org/10.3389/ti.2024.13220
Vancouver
Re Sartò GV, Alfieri C, Cosmai L, Brigati E, Campise M, Regalia A, et al. Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center. Transplant International. 2024;37. doi:10.3389/ti.2024.13220
BibTeX
@article{ReSart2024,
author = {Re Sartò, Giulia Vanessa and Alfieri, Carlo and Cosmai, Laura and Brigati, Emilietta and Campise, Mariarosaria and Regalia, Anna and Verdesca, Simona and Molinari, Paolo and Pisacreta, Anna Maria and Pirovano, Marta and Nardelli, Luca and Gallieni, Maurizio and Castellano, Giuseppe},
title = {Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center},
journal = {Transplant International},
year = {2024},
volume = {37},
doi = {10.3389/ti.2024.13220}
}
EUVIMED